Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial당뇨병과 같은 동반 질환이 없는 새로 진단된 COVID-19 감염 환자를 치료하기 위한 Hydroxychloroquine, Oseltamivir 및 Azithromycin의 코로나바이러스 치료(PROTECT) 평가를 위한 파키스탄 무작위 및 관찰 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-08-082022-08-13 Journal: Trials [Category] MERS, 임상, [키워드] 1:1 adaptive age allocation sequence approval authority Azithromycin baseline bioethics blinded Blinding board clinical Clinical improvement clinical status Cohort cohort study Combination combinations Committee Comorbidity comparator computer-generated Controlled trial coronavirus COVID-19 diabete diabetes Diabetes Mellitus diagnosed disease dissemination distress drug dyspneic Effectiveness eight element evaluate excluded expected Final flexibility Follow-up followed by Formal Gender groups Hospitalized Hydroxychloroquine hypertension Infection intervention group kidney Kidney failure lactating liver medical condition monotherapy multi-center multicenter nasal swab nucleic acid number objective observation open open label Ordinal Scale oseltamivir parameter participant patients patients with COVID-19 PCR positive pregnant Primary outcome Primary outcomes protocol public health qRT-PCR random randomization Randomized Randomized controlled trial randomized study recruited recruitment regimen Registered Registration reported respiratory distress Safety Sample size Self-isolation Seven seven-category ordinal scale Standard status Study protocol subject subsequent sulfate test negative tested three groups treat Treatment Trial twice a day Version virus website [DOI] 10.1186/s13063-020-04616-4 PMC 바로가기 [Article Type] Letter
Clinical outcomes of COVID-19 in Wuhan, China: a large cohort studyResearch Published on 2020-07-312022-10-28 Journal: Annals of Intensive Care [Category] COVID-19, [키워드] 95% CI acute respiratory syndrome Admission antiviral drug caused Characteristics clinical cohort study coronavirus Coronavirus disease 2019 COVID-19 COVID-19 patient D-dimer death demonstrated described Deterioration develop development diabete died discharged electronic medical record elevated feature Final Follow-up glucocorticoid greater higher risk illness onset In-hospital In-hospital death increased the risk independent risk factor information Inpatient interquartile range IQR Laboratory laboratory-confirmed large cohort Logistic regression lymphocytopenia mechanical ventilation median age Mortality multivariable logistic regression Non-invasive non-survivor oseltamivir outbreak outcome Patient patients with COVID-19 poor prognosis predict predictor progression reducing mortality Result retrospective risk factor Risk factors risk of death severe severe COVID-19 patients severe disease Severe patient severe patients single-center SOFA score Spread survivor Treatment was used with COVID-19 Wuhan Wuhan, China [DOI] 10.1186/s13613-020-00706-3 PMC 바로가기 [Article Type] Research
Differential Viral-Host Immune Interactions Associated with Oseltamivir-Resistant H275Y and Wild-Type H1N1 A(pdm09) Influenza Virus PathogenicityArticle Published on 2020-07-242023-06-07 Journal: Viruses [Category] 신종인플루엔자, [키워드] immunopathology Influenza oseltamivir pH1N1 Pneumonia resistance [DOI] 10.3390/v12080794 PMC 바로가기 [Article Type] Article
Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018코로나바이러스 질병에 대한 Oseltamivir: 2016년부터 2018년까지 유럽 1차 진료에서 공개 라벨, 실용주의, 무작위 대조 시험의 사후 탐색적 분석Research Published on 2020-07-232022-08-13 Journal: The British Journal of General Practice [Category] 임상, [키워드] 95% confidence interval ACHE activities added Analysis Care coronavirus Coronavirus infection Coronavirus infections CoV-229E CoV-KU1 CoV-NL63 CoV-OC43 COVID-19 defined determine Europe European Evidence Exploratory analysis Fever hazard ratio headache ILI Influenza interquartile range IQR management median time muscle ache NL63 Novel coronavirus OC43 Open-label oseltamivir participant Participants Patient patients with ILI positive post-hoc exploratory analysis Pragmatic presenting primary care Primary outcome randomised randomised controlled trial Randomised controlled trials reduce Research Result return SARS-CoV-2 Support symptomatic patient Symptomatic patients tested Time to recovery treated Treatment usual care usual care alone [DOI] 10.3399/bjgp20X711941 PMC 바로가기 [Article Type] Research
Genetic sequencing of influenza A (H1N1) pdm09 isolates from South India, collected between 2011 and 2015 to detect mutations affecting virulence and resistance to oseltamivirArticle Published on 2020-07-012023-06-23 Journal: Indian journal of medical microbiology [Category] 신종인플루엔자, [키워드] genetic sequencing H1N1 Influenza Mutation oseltamivir Phylogenetic analysis [DOI] 10.4103/ijmm.IJMM_20_83
A COVID-19 pandemic guideline in evidence-based medicine Reviews Published on 2020-06-262022-10-05 Journal: Evidence-based dentistry [Category] SARS, 임상, [키워드] 24 hour acute respiratory syndrome administration Admission albumin approach articles Baricitinib Blood Chinese Chloroquine claimed clinical guideline clinical study complications of COVID-19 concerning conducted coronavirus coronavirus disease Corticosteroids Course COVID-19 COVID-19 complications COVID-19 pandemic COVID-19 patients Critical Diagnosis discharge disease drug Endotracheal intubation English epidemiological Evidence Evolution exclusion criteria extracorporeal membrane oxygenation Factor Features groups help high risk home quarantine hospitalisation In-vitro information intensive care Intervention intravenous introduced Invasive mechanical ventilation laboratory result management management guideline Measures mild infection Neonatal Neonates observational studies oseltamivir Oxygen therapy Patient patients with COVID-19 positive airway pressure protein level reduce Remdesivir reported Reproduction number required response Result ruxolitinib SARS-CoV-2 sequence social distancing social isolation Spread spread of COVID-19 suggested symptomatic Symptoms the SARS-CoV-2 therapy Transmission Treatment treatment guidelines Trial trials vasopressors viral clearance vital sign [DOI] 10.1038/s41432-020-0105-7 [Article Type] Reviews
Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development EffortsInternal Medicine Published on 2020-06-262022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome available data Baricitinib candidate drug caused China clinical trial Comprehensive coronavirus country COVID-19 COVID-19 therapeutics death deaths development effective Favipiravir global pandemic globe Hydroxychloroquine losartan option oseltamivir positive Potential Remdesivir reported review ribavirin Ritonavir SARS-CoV-2 Spread Therapeutics Tocilizumab Treatment Trial umifenovir unmet need Vaccine development WHO World Health Organization [DOI] 10.7759/cureus.8845 PMC 바로가기 [Article Type] Internal Medicine
Modeling mitigation of influenza epidemics by baloxavirArticle Published on 2020-06-022022-10-04 Journal: Nature Communications [Category] SARS, 임상, 치료제, [키워드] Affect Antiviral approved baloxavir block clinical trial curtail death Diseases Epidemic Epidemics Health care Impact incidence infected case infected individual Infection Influenza Influenza virus inhibit kill mathematical modeling morbidity and mortality mRNA synthesis Older oseltamivir Prevent progeny reduce reducing Replication SARS-CoV2 Spread symptom onset Transmission Treatment Viral load virus virus replication [DOI] 10.1038/s41467-020-16585-y PMC 바로가기 [Article Type] Article
The association between treatment with heparin and survival in patients with Covid-19Article Published on 2020-05-312022-10-30 Journal: Journal of Thrombosis and Thrombolysis [Category] Coronavirus, MERS, [키워드] 95% CI added adjusted Admission age age and gender association associations Clinical data clinician Combination Community Controlled trial Coronavirus infections covariate COVID-19 died discharged home drug Effect Gender heparin hospital hospitals Hydroxychloroquine IQR logistic regression model lower mortality Mortality oseltamivir oxygen Patient patients Pulmonary embolism recorded remained required Ritonavir Spain Steroids survival temperature therapeutic regime thrombosis Tocilizumab transferred Treatment variable were used [DOI] 10.1007/s11239-020-02162-z PMC 바로가기 [Article Type] Article
Molecular docking analysis of N-substituted Oseltamivir derivatives with the SARS-CoV-2 main proteaseResearch-Article Published on 2020-05-312022-10-28 Journal: Bioinformation [Category] COVID-19, [키워드] 2019-nCoV 6LU7 Analysis binding chemotherapeutic drug code Corona coronavirus COVID-19 death derivative docking feature H5N1 influenza virus H5N1 inhibitor molecular docking molecular docking analysis novel oseltamivir protease SARS-CoV-2 the SARS-CoV-2 [DOI] 10.6026/97320630016404 PMC 바로가기 [Article Type] Research-Article